Borner, M.

Helbling, D.; Bodoky, G.; Gautschi, O.; Sun, H.; Bosman, F.; Gloor, Beat; Burkhard, R.; Winterhalder, R.; Madlung, Axel; Rauch, Daniel; Saletti, P.; Widmer, L.; Borner, M.; Baertschi, D.; Yan, P.; Benhattar, J.; Leibundgut, Elisabeth O.; Bougel, S.; Koeberle, D. (2013). Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07. Annals of oncology, 24(3), pp. 718-725. Oxford University Press 10.1093/annonc/mds519

Dawson, Heather; Hädrich, M.; Kölzer, V.; Inderbitzin, D.; Borner, M.; Zlobec, I.; Lugli, A. (2013). Intratumoral Budding (ITB) in Pre-Operative Biopsies: A Strong Indicator of Lymph Node Positivity in Colon and Rectal Cancer Patients. Laboratory investigation, 93(S1), 148A. Nature Publishing Group

Dawson, Heather; Hädrich, M.; Kölzer, V.; Inderbitzin, D.; Borner, M.; Zlobec, I.; Lugli, A. (2013). Intratumoral Budding (ITB) in Pre-Operative Biopsies:A Strong Indicator of Lymph Node Positivity in Colon and Rectal Cancer Patients. Modern pathology, 26, 148A. Nature Publishing Group

Scheithauer, W.; Mckendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C. (2003). Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. Annals of oncology, 14(12), pp. 1735-1743. Oxford University Press 10.1093/annonc/mdg500

Scholz, M.; Zehender, M.; Thalmann, G. N.; Borner, M.; Thöni, H.; Studer, U. E. (2002). Extragonadal retroperitoneal germ cell tumor: evidence of origin in the testis. Annals of oncology, 13(1), pp. 121-124. Oxford University Press 10.1093/annonc/mdf003

Crivellari, D.; Pagani, O.; Veronesi, A.; Lombardi, D.; Nolè, F.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Sessa, C.; Goldhirsch, A. (2001). High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. Annals of oncology, 12(3), pp. 353-356. Oxford University Press 10.1023/A:1011132609055

Pagani, O.; Sessa, C.; Nolè, F.; Crivellari, D.; Lombardi, D.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Martinelli, G.; Graffeo, R.; Zucchetti, M.; D'Incalci, M.; Goldhirsch, A. (2000). Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study. Annals of oncology, 11(8), pp. 985-991. Oxford University Press 10.1023/A:1008392927656

Pagani, O.; Sessa, C.; Martinelli, G.; Crivellari, D.; Buonadonna, A.; Thürlimann, B.; Hess, D.; Borner, M.; Bauer, J.; Zampino, G.; Zimatore, M.; Graffeo, R.; Riva, A.; Goldhirsch, A. (1999). Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer. Annals of oncology, 10(5), pp. 539-545. Oxford University Press 10.1023/A:1026437731354

Sessa, C.; Minoia, C.; Ronchi, A.; Zucchetti, M.; Bauer, J.; Borner, M.; De Jong, J.; Pagani, O.; Renard, J.; Weil, C.; D'Lncalci, M. (1998). Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. Annals of oncology, 9(12), pp. 1315-1322. Oxford University Press 10.1023/A:1008441416790